NCT02236026View on ClinicalTrials.gov

A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Healthy
Interventions
DRUG

Supratherapuetic dose of Nestorone

DRUG

Placebo

DRUG

Moxifloxacin

Trial Locations (1)

21225

Harbor Hospital, 3001 South Hanover Street, 7th Floor, Baltimore

Sponsors

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Population Council

OTHER

NCT02236026 - A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers | Biotech Hunter | Biotech Hunter